Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, established in 1941. Specializing in the research, development and commercialization of pharmaceutical products, Eisai focuses on addressing unmet medical needs across a range of therapeutic areas. The company places strong emphasis on human health care, aiming to improve patient outcomes through innovative treatments.
The company’s core business activities encompass drug discovery, clinical development, manufacturing and marketing of prescription pharmaceuticals. Eisai is widely recognized for its neurology franchise, most notably the Alzheimer’s therapy Aricept (donepezil), and has expanded into oncology with products such as Lenvima (lenvatinib). Its research platforms also include immuno-oncology, metabolic diseases and gastrointestinal disorders, leveraging both in-house capabilities and external collaborations.
Eisai maintains a global presence, with operations spanning Japan, North America, Europe and Asia. The company has established manufacturing facilities and research centers in key regions, as well as subsidiary offices to support regulatory affairs, distribution and medical affairs. Strategic partnerships with other pharmaceutical and biotechnology organizations further enhance Eisai’s ability to advance novel therapies and broaden patient access worldwide.
Leadership at Eisai is guided by President and Chief Executive Officer Haruo Naito, who has overseen the company’s strategic initiatives since April 2021. Under his direction, Eisai continues to prioritize its “human health care” philosophy, fostering innovation while maintaining a commitment to ethical standards and sustainable growth in the global healthcare market.
AI Generated. May Contain Errors.
MarketBeat All Access